Navigation Links
BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
Date:9/10/2007

BURLINGTON, Vt., Sept. 10 /PRNewswire/ -- BioMosaics Inc., a cancer biomarker development company, announced today that it has received CE marking for its proprietary products for the identification of Glypican-3 (GPC3) in human blood and in tissue as in vitro diagnostic tests. This will allow the GPC3 (Human Glypican-3) ELISA Kit for detecting GPC3 in human serum or plasma, and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone 1G12) to detect GPC3 in tissue by immunohistochemistry (IHC), to be marketed in the European Union.

GPC3, an oncofetal antigen, is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. The anti-GPC3 monoclonal antibody (MAb; clone 1G12) has also been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for ELISA detection of GPC3 in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions [Gastroenterology. 2003; 125:89-97]. Three recent major studies using BioMosaics GPC3 MAb have confirmed the early presence of GPC3 on hepatocellular carcinoma (HCC) and highly dysplastic cirrhotic nodules. [Wang XY et al, Human Pathology. 2006; 37(11):1435-41, Libbrecht et al, Am J Surg Pathol. 2006. 30(11):1405-1411, and Di Tommaso, Hepatology. 2007; 45(3):725-34].

Primary Liver Cancer, or Hepatocellular Carcinoma, is one of the most common and aggressive malignant tumors worldwide, causing an estimated one million deaths annually. Over 430,000 new cases of HCC are diagnosed each year. The main causative agents are hepatitis B virus (HBV), hepatitis C virus (HCV), as well as alcoholic cirrhosis and non-alcoholic steatohepatitis (NASH) which is associated with obesity, diabetes, and insulin resistance factors. The incidence of HCC has been steadily increasing over the past ten years and is expected to continue to rise over the next decade.

"BioMosaics recognizes the importance of developing new diagnostic tests that could more effectively target a specific type of cancer in the early stages. We are pleased that we have established these two high quality diagnostic products for the EU," said Dr. Ronald D. Guttmann, Executive VP Clinical Development.

About BioMosaics

BioMosaics is a biotechnology company located in Burlington, VT, engaged in the development and commercialization of innovative products for the early diagnosis, prediction, and monitoring of cancer.

Contacts:

BioMosaics Inc.

http://www.biomosaics.com

Mark Allegretta PhD; m.allegretta@biomosiacs.com

Ronald D. Guttmann MD; r.guttmann@biomosaics.com

+1-802-656-5443

Note: Statements in this news release that are not historical facts are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.


'/>"/>
SOURCE BioMosaics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
5. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
8. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NEW YORK , Jan. 16, 2017 /PRNewswire/ ... global peripherally inserted central catheters market for the ... is to offer updates and information related to ... catheters market. This comprehensive market study demonstrates the ... current environment and future status of the global ...
(Date:1/16/2017)... 16, 2017   The Harrington Discovery Institute ... Ohio , has announced the 2017 recipients ... discoveries of physician-scientists whose research shows promise to ... Harrington Discovery Institute – part of The Harrington ... need in academic medicine: to advance early breakthroughs ...
(Date:1/16/2017)... and PUNE, India , January 16, 2017 ... Market Research, titled, "Vital Signs Monitoring Devices Market by Type ... projects that the global vital signs monitoring devices market size ... reach $5,491 million by 2022, growing at a CAGR of ... was the leading regional market in global vital signs ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive ... an innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will ... sell wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all types ... to test for, as well. The money spent screening for and treating cancer in ... U.S. screen patients for cancer more than in any other country that has an ...
(Date:1/15/2017)... , ... January 15, 2017 , ... ... Community Outreach is a program that strives to better communities around the world ... locations’ community. It also provides the opportunity for team members to become involved ...
(Date:1/15/2017)... ... ... Wondering where to go this Valentine's Day? Well, there is a solution to ... feast in the comfort of your own home. Lobster Gram is introducing two new ... until February 15th, 2017. , Romantic Dinner one is Lobster Gram's "Love at ...
(Date:1/14/2017)... Florida (PRWEB) , ... January 14, 2017 , ... AgileMinder ... Scale. , The Emoji Scale is now available on Apple as a fun, ... emoji ratings simply by choosing one of the ten color coded values on The ...
Breaking Medicine News(10 mins):